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Eleven patients with drug-resistant pandemic (H1N1) 2009 were identified in South Korea during May 
2009–January 2010. Virus isolates from all patients had the H275Y mutation in the neuraminidase gene. 
One isolate had the I117M mutation. Of the 11 patients, 6 were <59 months of age, and 5 had underlying 
immunosuppressive conditions. 
The Korea Centers for Disease Control and Prevention asked clinicians to report all 
patients with suspected cases of drug-resistant pandemic (H1N1) 2009 when these patients 
showed treatment failure for oseltamivir or had unusually prolonged viral shedding (defined as 
>5 days after the onset of symptoms) (1). We report nationwide surveillance data on the 
epidemiologic and clinical characteristics of patients infected with pandemic (H1N1) 2009 in 
South Korea. 
The Study 
From the first reported infected patient in May 2009 through January 2010, a total of 
740,835 patients in South Korea were reported as having pandemic (H1N1) 2009 virus infection. 
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A total of 225 patients (0.03%) died of disease related to pandemic (H1N1) 2009. During this 
period, physicians in local clinics and tertiary hospitals sent specimens from 67 patients who 
were suspected of having drug-resistant pandemic (H1N1) 2009 to the Korea Centers for Disease 
Control; 11 patients (16%) had drug-resistant virus (Figure). After confirmation of drug 
resistance, Epidemic Intelligence Service officers obtained clinical and epidemiologic data by 
medical record review and interviews with household contacts and attending physicians for all 
patients. 
To investigate whether virus contained genetic markers associated with resistance to 
antiviral drugs, a conventional genotyping assay (sequencing) was performed, and neuraminidase 
(NA) and matrix 2 genes were sequenced. All 11 patients had virus with a histidine-to-tyrosine 
mutation at residue 275 of the NA protein (H275Y); 1 patient also had virus with an I117M 
mutation (Figure). Detailed molecular epidemiologic data and genetic characteristics of the 
isolates are described elsewhere (2). 
Of the 11 patients, 6 were <59 months of age and 5 had underlying immunosuppressive 
conditions; only 1 patient was immunocompetent and >59 months of age (Table). Three patients 
from whom samples before and after treatment with oseltamivir were available showed evidence 
of having acquired the H275Y mutation during oseltamivir therapy. None of the 11 patients 
received oseltamivir chemoprophylaxis. 
We also tested 100 persons who had contact with the 11 patients for possible 
transmission of drug resistance. Eight of 100 were confirmed as having been infected with 
pandemic (H1N1) 2009 virus before the 11 patients were infected. Influenza-like illnesses 
developed in the 11 patients a median of 2 days (range 1–7 days) after the 8 contact persons were 
confirmed as having pandemic (H1N1) 2009. Five of the 8 contact patients were children; none 
had an immunosuppressive condition or were given oseltamivir chemoprophylaxis before illness; 
and 7 of 8 were <59 months of age. Oseltamivir-resistance tests were not performed for these 8 
patients because they all received oseltamivir therapy and their clinical symptoms resolved. 
Therefore, the possibility of transmitted resistance from contact patients was not demonstrated in 
this study. 
All 11 patients were initially given the usual dose of oseltamivir (75 mg 2×/day in 
adults). After detection of oseltamivir resistance, treatment regimens were as follows: 3 patients 
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were given high-dose oseltamivir (150 mg 2×/day in adults), 3 patients were given combination 
therapy (oseltamivir and amantadine; oseltamivir and peramivir; and oseltamivir, amantadine, 
and ribavirin, respectively); 3 patients were given zanamivir nasally; and 2 patients continued to 
receive oseltamivir. 
Seven of the 11 patients had complications during treatment: 6 had viral or secondary 
bacterial pneumonia and 1 had acute respiratory distress syndrome (Table). Three patients died 
of pandemic (H1N1) 2009. Patient 3 died 15 days after confirmation of infection with pandemic 
(H1N1) 2009 virus and 10 days after the emergence of oseltamivir-resistant virus. Patient 4 died 
15 days after confirmation of infection and 4 days after emergence of oseltamivir-resistant virus. 
Patient 8, who was infected with virus that had H275Y and I117M mutations, died 18 days after 
confirmation of infection and 4 days after the emergence of oseltamivir-resistant virus. 
Conclusions 
Our nationwide surveillance of drug-resistant pandemic (H1N1) 2009 in South Korea 
indicated that most patients were children (<59 months of age) or immunocompromised. All 
isolates had the H275Y mutation in the NA protein, and 1 isolate also had the I117M mutation in 
the same protein. 
Our finding that oseltamivir resistance developed in immunocompromised patients is 
consistent with those of recent case reports that described development of oseltamivir resistance 
in immunosuppressed patients receiving this drug (3,4). A recent study in Australia reported that 
4 of 32 adult oncology and hematology patients were infected with oseltamivir-resistant virus 
with the H275Y mutation (5). In 3 of our patients (patients 3, 5, and 11) drug-resistant isolates 
appeared <5 days after initiation of oseltamivir therapy. Thus, we suggest that physicians be alert 
to emergence of oseltamivir-resistant pandemic (H1N1) 2009, particularly if there is treatment 
failure with oseltamivir or prolonged viral shedding is evident. 
More than half of our patients were <59 months of age, indicating that a younger age may 
be a risk factor for infection with drug-resistant pandemic (H1N1) 2009. Clinical trials have 
reported oseltamivir resistance in <5.5% of children with seasonal influenza (6). Explanations for 
the higher rate of drug resistance in children than in adults are that children have a more 
protracted course of influenza, longer viral shedding times, and higher viral titers (7). Another 
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explanation might be that we cannot rule out suboptimal dosing of oseltmaivir in children, 
although World Health Organization dose standards were used (8) and all pharmacies were given 
instructions on emergency compounding of oseltmaivir. 
Development of resistance appeared to be caused by sporadic mutations. We found no 
evidence of transmission. Availability of pretreatment and posttreatment samples indicated that 
resistance to oseltamivir developed during treatment in >3 patients. One case report (9), 1 report 
of a cluster of cases in Vietnam (10), and 1 outbreak in a hematologic ward (11) documented 
patient-to-patient transmission of oseltamivir-resistant virus. One of our patients was infected 
with virus that had a novel NA mutation (I117M). A previous study indicated that the I117V 
mutation in avian influenza virus (H5N1) was associated with low-level oseltamivir resistance 
(12). The I117M mutation of NA may contribute to oseltamivir resistance, but it is not clear 
whether isolates with these 2 NA mutations have higher levels of resistance or virulence than the 
H275Y NA mutant. 
We found few patients with drug-resistant pandemic (H1N1) 2009 in South Korea. 
However, our study was based on the nationwide surveillance system for drug resistance among 
patients with suspected oseltamivir treatment failures, which is different from other surveillance 
systems, in which all isolated viruses are tested. Thus, we cannot report the prevalence of drug-
resistant pandemic (H1N1) 2009 and risk factors for drug-resistant virus infection in South 
Korea. Further studies are needed to monitor oseltamivir resistance, especially in 
immunosuppressed or pediatric patients when treatment failure with oseltamivir or prolonged 
viral shedding occur. Additional studies are also needed to determine proper oseltamivir dosing 
for children. 
Dr. Shin is an epidemic intelligence service officer at the Korea Centers for Disease Control and 
Prevention, Seoul, South Korea. His research interests include respiratory viruses and pediatric infections. 
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Table. Characteristics of 11 patients with oseltamivir-resistant 
pandemic (H1N1) 2009, South Korea* 
Characteristic Value 
Age, y, median (range) 5 (1–63) 
Male sex 6 
No. at high risk for influenza-related complications  
 <59 mo of age 6 
 Chronic medical disorders 9 
  Neurologic 3 
  Hematologic 3 
  Metabolic, including diabetes† 2 
  Pulmonary, including asthma 1 
  Renal† 1 
  Cardiovascular, excluding hypertension 0 
  Hepatic disorder 0 
 Immunocompromised‡ 5 
Median days from symptom onset to viral isolation 
(range) 
2 (0–9) 
Median days from symptom onset to development of 
resistance 
8 
No. hospitalized 11 
Hospitalization duration, d, median (range) 15 (6–53) 
Symptom duration, d, median (range) 17 (6–22) 
No. with respiratory illness related to influenza 11 
 Viral pneumonia 6 
  Secondary bacterial pneumonia 2 
  Secondary bacterial pneumonia and acute  
  respiratory distress syndrome 
1 
Reasons for requesting drug-resistance testing  
 Treatment failure 9 
 Prolonged viral shedding 2 
No. with co-infections§ 3 
Outcome  
 Cured 8 
 Died¶ 3 
*Specimens were obtained from oropharyngeal (n = 7) and 
nasopharyngeal (n = 2) swabs, nasopharyngeal washings (n = 1), and 
brochoalveolar lavage fluid (n = 1). 
†One patient had diabetes and chronic renal failure. 
‡Patients who had underlying diseases such as HIV infection, malignancy, 
liver cirrhosis, or chronic renal failure, or patients receiving 
immunosuppressive treatment. 
§Carbapenem-resistant Pseudomonas aeruginosa (patient 3), 
carbapenem-resistant Acinetobacter baumanii (patient 4), and penicillin-
susceptible Streptococcus pneumonia (patient 10). 
¶Of the 3 patients, 1 was infected with carbapenem-resistant P. 
aeruginosa (patient 3) and 1 was infected with carbapenem-resistant A. 
baumanii (patient 4). 
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 Figure. Clinical course and outcome of 11 patients with oseltamivir-resistant pandemic (H1N1) 2009, 
South Korea. Symptom aggravation was defined as influenza-related symptoms that worsened 
regardless of new infiltrations seen by chest radiography. Symptom improvement was defined as 
influenza-related symptoms (nasal stiffness, sore throat, cough, myalgia, fatigue, headache, and fever) 
that were absent or mild. All doses of oseltamivir were given 2×/d. ED, emergency department. 
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